Publication & Citation Trends
Publications
19 total
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804) PDF
Cited by 95
OpenAlex
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Cited by 63
OpenAlex
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317 PDF
Cited by 114
OpenAlex
Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer PDF
Cited by 312
OpenAlex
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer PDF
Cited by 328
OpenAlex
Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma
Cited by 77
OpenAlex
Research Topics
Renal cell carcinoma treatment
(10)
Chemotherapy-induced cardiotoxicity and mitigation
(4)
Renal and related cancers
(4)
Bladder and Urothelial Cancer Treatments
(3)
Cancer Treatment and Pharmacology
(3)
Affiliations
Fox Chase Cancer Center
Albert Einstein College of Medicine
City Of Hope National Medical Center
Beth Israel Deaconess Medical Center
Cleveland Clinic